CCL2 and neoplasm: Expression of CCR2, the main CCL2 receptor, in both TNC+ and TNC− NT193 breast tumor cells was below 0.5% of HPRT for all timepoints in both cell types, suggesting that whilst tumor cells are a major source of CCL2 (Figure 1H–J), they are not responding in an autocrine manner to this chemokine.